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Epithelial ovarian cancer is the leading cause of gynecologic cancer 
death and the fifth most common cause of cancer mortality among 
women in the United States (1). The majority of patients are diag-
nosed with advanced (ie, stages III and IV) disease, for which the 
standard treatment is aggressive surgical debulking followed by six 
to eight cycles of platinum-based chemotherapy, which is typically 
delivered concurrently with a taxane (2). Because of high toxicity, 
up to 42% of patients are unable to complete therapy as initially 
prescribed (3). To date, no good clinical measures for prediction of 
response exist; as a result, approximately 30% of patients undergo 
multiple cycles of therapy, with little or no benefit, before they are 
identified as being chemoresistant. The remaining 70% of patients 
initially achieve a complete response (CR), but more than 75% 
relapse within a few years (3). Therefore, it is important to develop 
prognostic tools to identify patients with worse predicted outcomes 
and redirect them to alternate therapies that may be potentially 
more efficacious, such as radiation (4) or alternate chemotherapeutic 
agents (eg, topotecan) (5).
Several  groups  have  used  microarray-based  gene  expression 
profiling to generate prognostic and/or molecular subtype signa-
tures (6–14). For example, Berchuck et al. (9) analyzed 65 patients 
with serous ovarian cancers, including 54 stage III and stage IV 
cancers, and built classifiers incorporating up to 26 genes that 
distinguished  short-  and  long-term  survivors  (10).  These  genes 
represented diverse cellular functions, such as cleavage stimulation 
factor subunit 3 (CSTF3), which is involved in mRNA processing 
(15), and ATP-binding cassette, subfamily D, member 3 (ABCD3), 
which is involved in peroxisome assembly (16). Tothill et al. (11) 
analyzed 285 serous and endometrioid tumors of the ovary, perito-
neum, and fallopian tube, and performed k-means clustering, a 
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bioinformatics tool for unsupervised class discovery of molecular 
subtypes (17). They identified six molecular subtypes that repre-
sented varying tumor serous low malignant potential tumors and 
showed relative overexpression of mitogen-activated protein kinase 
pathway  genes  (dual  specificity  phosphatase  4  [DUSP4],  dual   
specificity phosphatase 6 [DUSP6], serine [or cysteine] peptidase 
inhibitor  5A  [SERPINA5],  mitogen-activated  protein  kinase  5 
[MAP3K5], and sprout homolog 2 [SPRY2]), and molecular sub-
type C5 represented a high-grade (ie, histological grade 3) serous 
ovarian tumor subtype defined by genes expressed in mesenchymal 
cell  development  (homeobox  A7  [HOXA7],  homeobox  A9 
[HOXA9], homeobox A10 [HOXA10], homeobox D10 [HOXD10], 
and sex-determining region Y-box 11 [SOX11]). These gene sig-
natures, however, have not yet achieved widespread use. This may 
be partly because of concerns of reproducibility, which may stem 
from incorporation of sets of unrelated genes, and computer-based 
algorithms that do not incorporate biologic rationale during gene 
selection. In these published studies, the biological importance of 
the selected genes is discussed retrospectively rather than examined 
prospectively.
In this study, we hoped to show the strength of using a hypothesis-
driven approach to improve reproducibility of gene expression–
based scores. We hypothesized that ovarian cancer patients with 
poor vs favorable outcomes, following platinum-based chemo-
therapy, have tumors that show differential expression of genes 
involved in repair of platinum-induced DNA damage. The ataxia-
telangiectasia-mutated (ATM) pathway is known to be activated in 
response to platinum-induced DNA damage (18), resulting in 
phosphorylation and stabilization of tumor protein p53 (TP53) 
(19), and may function in concert with Fanconi anemia (FA) genes 
to maintain genomic integrity (20). It is well known that FA/
homologous recombination (FA/HR) pathway genes are critical in 
repair of complex double-stranded lesions induced by platinum 
agents (21,22). Nucleotide excision repair (NER) is the principal 
pathway  through  which  intra-  and  interstrand  crosslinks  are 
repaired (23), along with translesion synthesis (TLS), which allows 
DNA replication to continue despite blockage from DNA damage 
(24). Our goal, therefore, was to develop a molecular score based 
on the expression levels of genes in these pathways that could be 
predictive for survival and other measures of clinical outcome for 
ovarian cancer patients treated initially with a standard platinum-
based chemotherapy regimen.
Methods
Identification of DNA Repair Pathway Genes
Based on a literature review and our knowledge of DNA repair 
pathways, we devised a set of 151 DNA repair genes with docu-
mented roles in the following DNA repair pathways: ATM (18), 
base excision repair (BER) (25–28), FA/HR (21,22), mismatch repair 
(MMR) (29–31), non-homologous end joining (NHEJ) (32–34), 
NER (23), TLS (24), cross-link repair (XLR) (35–37), recQ helicase 
pathway (RECQ) (38,39), and other (40–43) (Supplementary Table 1, 
available online). Based on published data, genes in the ATM (18), 
FA/HR (21,22), NER (23), and TLS (24) pathways were selected 
from the set of 151 genes for the development of a score predictive 
of outcomes following platinum-based therapy.
Patient Samples
We extracted clinical data for 511 patients with serous ovarian 
cystadenocarcinoma from The Cancer Genome Atlas (TCGA) 
database (44) website (http://tcga-data.nci.nih.gov) on February 
17, 2011, representing the largest available dataset of epithelial 
ovarian cancer gene expression profiles (see Supplementary Table 2, 
available online, for further details on which ovarian cancer sam-
ples were included in this study). These were all the patients for 
whom full sets of tumor gene expression data were available for 
download. Ovarian cancer samples were categorized by the TCGA 
into four molecular subtypes on the basis of gene cluster content: 1) 
immunoreactive, characterized by increased representation of 
T-cell chemokine ligand genes; 2) differentiated, characterized by 
genes suggestive of more mature development; 3) proliferative, 
characterized by high expression of proliferation markers and tran-
scription factors; and 4) mesenchymal, characterized by stromal 
component genes (44). Clinicopathologic characteristics, and data 
on molecular subtype, are shown in Table 1. Median year of path-
ological diagnosis was 2004 (range = 1992–2009), and median age 
at diagnosis was 59 years (range = 30–89 years). Because our aim 
was to develop a score predictive of outcomes following standard 
platinum-based chemotherapy, we focused on the 304 patients 
with advanced (stages III and IV) ovarian cancer who received a 
platinum and taxane regimen as first-line treatment. The control 
group consisted of advanced-stage (stages III and IV) patients   
(n = 161) who did not receive platinum and taxane therapy.
CONTEXT AND CAVEATS
Prior knowledge
At present, there are no effective prognostic tools for prediction of 
response in ovarian cancer patients, a majority of whom are diag-
nosed with an advanced stage (stages III and IV) and undergo sur-
gical debulking followed by and platinum-based chemotherapy.
Study design
Gene  expression  data  was  extracted  from  The  Cancer  Genome 
Atlas (TCGA) database for patients with advanced ovarian cancer, 
and a molecular score was developed by focusing exclusively on 
the genes involved in platinum-induced DNA damage repair path-
ways.  Patients  were  divided  into  low  (0–10)  and  high  (11–20) 
scores, and the prognostic value of the score for overall survival, 
recurrence-free survival, and progression-free survival was assessed. 
Data were validated in two independent datasets.
Contribution
Patients with high scores showed statistically significant associations 
with improved overall survival compared with patients with low 
scores. The score was predictive of overall survival, recurrence-
free  survival,  and  progression-free  survival  in  ovarian  cancer 
patients who received first-line platinum-based chemotherapy.
Implication
This score has the potential to become an important prognostic 
tool to determine whether advanced-stage ovarian cancer patients 
will benefit from first-line platinum-based chemotherapy.
Limitation
The score has not been tested prospectively in a clinical trial.
From the Editors
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Gene Expression Data
Gene expression profiles are routinely acquired by the TCGA for 
tumors included in their database using three widely used microar-
ray  platforms:  Agilent  Custom  244K  (Agilent  Technologies, 
Santa Clara, CA), Affymetrix Human Exon 1.0, and Affymetrix 
HT_HG-U133A (Affymetrix, Santa Clara, CA). We downloaded 
from the TCGA website all available data as of February 17, 2011. 
For our analyses, we used the level 3 data, which provides, for each 
tumor,  expression  levels  for  each  gene  profiled  by  the  three 
microarray platforms. The expression values for each gene were 
normalized by subtracting from it the mean value of the 511 tumor 
specimens. The three microarray platforms assessed many, but not 
all, of the same genes. For our analyses, the median normalized 
values among the three platforms were used.
Construction of a DNA Repair Pathway–Focused Score
Kaplan–Meier log-rank P values were calculated to identify a 
subset of genes whose expression values showed a trend associated 
with overall survival (OS) (P < .15) (Supplementary Figure 1, avail-
able online). This cut point, which included the top quartile of 
genes by P value, was selected because representation of each of 
the DNA repair pathways was lost with more stringent cut points. 
Also, other cut points were not examined to minimize retrospec-
tive optimization. For each patient’s tumor, a point was given for 
each gene for which higher than median expression was associated 
with longer survival, and vice versa. The sum of these points 
constituted our score. The DNA repair pathway–focused score 
(referred to as “the score”) included only genes in the ATM, FA/HR, 
NER, and TLS pathways (Table 2). The scores were categorized 
Table 1. Clinicopathologic characteristics of ovarian cancer patients in The Cancer Genome Atlas (TCGA) dataset*
Characteristic
All patients (n = 511) Advanced (stage III–IV) patients (n = 464)
No. of patients Median OS (95% CI), y No. of patients Median OS (95% CI), y
Age (median 59, range 30–89), y      
  ≤59 262 4.1 (3.7 to 4.5) 242 4.1 (3.6 to 4.4)
  ≥60 242 3.2 (2.8 to 3.5) 222 3.0 (2.8 to 3.4)
Stage†      
  I 15 6.7 (6.7 to ∞) — —
  II 23 5.9 (3.7 to ∞) — —
  III 383 3.7 (3.3 to 4.0) 383 3.7 (3.3 to 4.0)
  IV 81 2.7 (2.2 to 4.2) 81 2.7 (2.2 to 4.2)
Grade‡      
  1 5 5.4 (4.5 to 6.2) 5 5.4 (4.5 to 6.2)
  2 61 4.6 (3.5 to 6.8) 49 4.0 (3.2 to 5.1)
  3 428 3.5 (3.2 to 4.0) 398 3.4 (3.0 to 3.8)
Initial chemotherapy      
  Platinum and taxane 331 4.0 (3.6 to 4.5) 304 3.8 (3.4 to 4.2)
  Cisplatin 43 3.8 (3.0 to 4.7) 42 3.8 (3.0 to 4.7)
  Carboplatin 286 4.0 (3.5 to 4.4) 260 3.7 (3.2 to 4.1)
  Oxaliplatin 2 — 2 —
  Non-platinum and taxane 126 3.7 (3.1 to 4.1) 121 3.5 (3.0 to 4.0)
Response to primary therapy      
  Platinum and taxane 289 4.2 (3.7 to 4.6) 264 4.0 (1.8 to 3.0)
  CR 208 4.8 (4.1 to 5.9) 188 4.8 (4.1 to 5.7)
  Non-CR 81 2.8 (1.8 to 3.2) 78 2.7 (1.8 to 3.0)
  Non-platinum and taxane 121 4.0 (3.3 to 4.5) 101 3.6 (3.0 to 4.3)
  CR 80 4.7 (4.0 to 5.9) 67 4.4 (3.7 to 4.9)
  Non-CR 41 2.5 (1.9 to 3.2) 34 2.5 (1.7 to 3.1)
Surgical debulking      
  0–10 mm residual tumor 329 3.7 (3.4 to 4.0) 300 3.5 (3.2 to 3.8)
  ≥11 mm residual tumor 128 3.0 (2.6 to 3.5) 116 3.1 (2.6 to 3.6)
TCGA tumor/gene subtype      
  Differentiated 134 3.7 (3.2 to 4.0) 83 3.5 (2.9 to 4.0)
  Immunoreactive 104 4.3 (3.3 to 5.9) 68 4.2 (3.0 to 5.9)
  Mesenchymal 107 3.4 (2.6 to 4.1) 67 3.8 (2.4 to 5.2)
  Proliferative 135 3.5 (3.0 to 4.0) 79 4.1 (3.2 to 5.0)
  N/A 24 6.2 (2.8 to ∞) 7 3.6 (0.8 to 6.2)
*  We extracted clinical data for 511 patients with serous ovarian cystadenocarcinoma from TCGA (44) website (http://tcga-data.nci.nih.gov) on February 17, 2011. 
Ovarian cancer samples were categorized by the TCGA into four molecular subtypes on the basis of gene cluster content: immunoreactive, characterized by 
increased representation of T-cell chemokine ligand genes; differentiated, characterized by genes suggestive of more mature development; proliferative, characterized by 
high expression of proliferation markers and transcription factors; and mesenchymal, characterized by stromal component genes. Clinicopathologic characteristics 
are shown, and Kaplan–Meier survival analyses were performed to estimate OS. Because our aim was to develop a score predictive of outcomes in advanced-stage 
(stages III and IV) ovarian cancer patients, we also present data that is specific for this group. CR = complete response; CI = confidence interval; OS = overall 
survival; — = not applicable.
†  Stage based on International Federation of Gynecology and Obstetrics (FIGO) (46).
‡  Grade based on histological features (47).jnci.oxfordjournals.org    JNCI | Articles 673
as “low” (ie, scores 1–10) or “high” (ie, scores 11–20), based on the 
range of scores observed in the study, which divided the patients into 
two categories with equal ranges; other thresholds were not examined 
except, as noted, to minimize retrospective optimization.
Some pathways (BER, NHEJ, MMR, RECQ, XLR, and “other”) 
were excluded because of less-established or no known role in 
platinum-induced DNA damage repair. To further explore the use 
of biologic rationale in molecular score construction, we used the 
17 genes from these pathways to form an alternate 17-gene score.
Validation Datasets
Two previously published ovarian cancer datasets with openly 
accessible microarray and clinical data [Berchuck et al. (9) and 
Tothill et al. (11); referred as “Berchuck dataset,” and “Tothill 
Table 2. Genes in platinum-specific DNA repair pathways that 
were used to construct the score*
Gene Pathway Survival† P‡
ATM ATM high .12
H2AFX ATM high .026
MDC1 ATM high .10
RNF8 ATM high .020
TOP2A ATM high .11
BRCA2 FA/HR low .069
C17orf70 FA/HR high .059
FANCB FA/HR high .11
FANCE FA/HR high .055
FANCF FA/HR high .006
FANCG FA/HR high .047
FANCI FA/HR high .13
PALB2 FA/HR high .034
MUS81 FA/HR high .11
NBN FA/HR low .083
SHFM1 FA/HR high .12
DDB1 NER high .045
ERCC8 NER low .11
RAD23A NER high .034
XPA NER low .14
MAD2L2 TLS high .11
POLH TLS high .15
UBE2I TLS high .049
*  The 23-gene set was constructed with genes in the ATM (18), Fanconi 
Anemia (FA)/homologous recombination (HR) (21,22), nucleotide excision 
repair (NER) (23), and translesion synthesis (TLS) (24) pathways. ATM = ataxia 
telangiectasia mutated; BRCA2 = breast cancer 2, early onset; C17orf 70 = 
chromosome 17 open reading frame 70 (FAAP100); DDB1 = damage-specific 
DNA binding protein 1; ERCC8 = excision repair cross-complementing rodent 
repair deficiency, complementation group 8; FANCB = Fanconi anemia, com-
plementation group B; FANCE = Fanconi anemia, complementation group E; 
FANCF = Fanconi anemia, complementation group F; FANCG = Fanconi 
anemia, complementation group G; FANCI = Fanconi anemia, complemen-
tation group I; H2AFX = histone 2A family, member X; MDC1 = mediator 
of DNA damage checkpoint 1; RNF8 = ring finger protein 8; MAD2L2 = 
mitotic arrest deficient-like 2; MUS81 = MUS81 endonuclease homolog (S. 
cerevisiae); NBN = nibrin; PALB2 = partner and localizer of BRCA 2 (FANCN); 
POLH = polymerase (DNA directed), eta; RAD23A = RAD23 homolog A 
(S. cerevisiae); SHFM1 = split hand/foot malformation (ectrodactyly) type 
1; TOP2A = topoisomerase (DNA) II alpha; UBE2I = ubiquitin-conjugating 
enzyme E2I; XPA = xeroderma pigmentosum, complementation group A.
†  For each gene, “high” means higher than median gene expression was 
associated with improved overall survival in The Cancer Genome Atlas data-
set, and “low” means higher than median gene expression was associated 
with worse overall survival (P values are presented). Kaplan–Meier analyses 
were performed to estimate survival.
‡  P values were calculated using a two-sided log-rank test.
dataset,” respectively] were used as validation datasets. After com-
pletion of all analyses using the TCGA dataset, the analyses were 
replicated in these two datasets for validation of the results, to the 
extent feasible based on available data.
Statistical Analysis
Median and 5-year OS for each scoring group (high vs low) were 
calculated using the Kaplan–Meier method, and statistical signifi-
cance was assessed using the log-rank test. Hazard ratios (HRs) for 
all-cause mortality and 95% confidence intervals (CIs) were calcu-
lated using the Cox proportional hazards analysis. Assumptions of 
proportionality were confirmed for the Cox proportional hazards 
analyses by generating Kaplan–Meier survival estimate curves (eg, 
for high vs low scoring groups), and observing that the curves did 
not intersect with each other. These analyses were performed with the 
TCGA dataset, four TCGA molecular subtype subsets (immunoreac-
tive, differentiated, proliferative, and mesenchymal), and the two 
validation  datasets  (Berchuck  and  Tothill).  Distribution  of  scores 
among the four molecular subtypes was assessed as a continuous 
and as a categorical variable using analysis of variance (ANOVA).   
CR,  partial  response  (PR),  stable  disease  (SD),  and  progressive 
disease (PD) were assessed per Response Evaluation Criteria In 
Solid Tumors (RECIST) criteria (45). Univariate and multivariable 
analyses were performed using Cox proportional hazards models 
incorporating the score (low vs high) and known prognostic clinical 
factors, including response to primary therapy (CR vs non-CR), 
age at diagnosis (≤59 vs ≥60 years), International Federation of 
Gynecology and Obstetrics (FIGO) stage (46) (III vs IV), histolog-
ical  grade  (47)  (1–2  vs  3),  and  extent  of  surgical  debulking 
(0–10 vs ≥11 mm residual tumor), as categorical variables.
To assess the potential clinical impact of the score, multivari-
able  analyses  using  the  Cox  proportional  hazards  models  were 
performed with the score as a continuous variable, and/or the 
following set of clinical variables: age as a continuous variable, 
grade 1–4 or unknown as a categorical variable, and stages IIIA–C 
or stage IV as a categorical variable (Table 3). None of the clinical 
variables showed P values less than .05, unlike the score, but all 
were  included  so  that  receiver  operating  characteristic  (ROC) 
curves could be generated to compare the models with and without 
inclusion of the score. To generate the ROC curves, patients were 
classified as surviving either longer or shorter than the median OS, 
excluding patients who were alive for durations less than the 
median OS at last follow-up. Logistic fit of low vs high survival 
category by cumulative hazard (the product of the hazard ratios of 
each  incorporated  variable)  was  performed.  Area  under  the  curve 
(AUC) values were calculated from the ROC curves. For validation, 
the HRs calculated above were applied to the Berchuck dataset, which 
was the one that included data on the same clinical variables.
The Pearson correlation coefficient was calculated to assess the 
relationship between the score and each of the following: median 
OS, recurrence-free survival (RFS), progression-free survival (PFS), 
and CR, excluding the single patient in the TCGA dataset with a 
score of 3, which appeared to be an outlier. The Kaplan–Meier 
method  and  the  log-rank  test  were  used  to  assess  RFS  after 
achieving a CR, as well as PFS, in patients with low vs high scores. 
The proportion of patients in each treatment response group (CR, 
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because representation of each DNA repair pathway was lost with 
more stringent cut points) with OS in serous ovarian cystadenocar-
cinoma  patients  (n  =  511)  in  the  TCGA  dataset  (Table  2  and 
Supplementary  Figure  1,  available  online).  Median  OS  for  the 
entire dataset was 3.7 years (range = 8 days to not reached).   
A molecular score was devised for each ovarian cancer patient by 
assigning a point for each gene for which higher than median 
expression was associated with longer survival, and vice versa, and 
obtaining the sum of these points. We divided patients into two 
groups by the median score—patients with low scores (scores 
1–10) and patients with high scores (scores 11–20). This cut point 
seemed to be the simplest to apply clinically and because it divided 
a similar number of patients into each group. The association 
between OS (median OS and 5-year OS) and low vs high score was 
analyzed. Low scores were associated with worse OS (low vs high 
score, median OS = 3.0 years [95% CI = 2.8 to 3.3 years] vs 4.5 years 
[95% CI = 4.0 to 4.9 years]; 5-year OS = 17% [95% CI = 11% to 
24%] vs 40% [95% CI = 33 to 49%]; log-rank P < .001). The score 
demonstrated  greater  ability  to  distinguish  worse  vs  improved 
survival outcomes in patients who received a platinum and taxane 
regimen as first-line chemotherapy (low vs high score, median 
OS = 3.2 years [95% CI = 2.7 to 3.5 years] vs 4.7 years [95% CI = 
4.2 to 5.7 years]; 5-year OS = 17% [95% CI = 10% to 28%] vs 46% 
[95% CI = 36% to 57%]; log-rank P < .001) (Figure 1, A) com-
pared with those who did not receive this treatment (low vs high 
score, median OS = 3.3 years [95% CI = 2.8 to 4.0 years] vs 4.0 
years [95% CI = 3.0 to 4.8 years]; 5-year OS = 19% [95% CI = 
10% to 34%] vs 31% [95% CI = 29% to 46%]; log-rank P = .017) 
(data not shown in the figure).
Next, we performed a univariate analysis to assess whether the 
score was associated with OS for patients treated with a platinum 
and taxane regimen in the TCGA dataset from which it was 
derived. Low scores were associated with worse OS and high 
scores with improved OS (high vs low scores, HR of death = 0.44, 
95% CI = 0.33 to 0.61, P < .001). We then assessed whether the 
score was associated with OS in two validation sets and found a 
similar  statistically  significant  association  in  the  Berchuck  and 
Tothill datasets (high vs low scores, Berchuck dataset, HR of death = 
0.33, 95% CI = 0.13 to 0.86, P = .013; Tothill dataset, HR of death = 
0.61, 95% CI = 0.36 to 0.99, P = .044) (Figure 1, B). All patients in 
the  Berchuck  dataset  received  platinum-based  therapy,  and  the 
score identified low vs high survival subtypes (low vs high score, 
median OS, 1.8 years [95% CI = 0.8 to 2.8 years] vs 2.9 years [95% 
CI = 2.3 to ∞]; 5-year OS, 0% vs 35% [95% CI = 15% to 63%], P 
= .013). The Tothill dataset had a mixed population containing 
patients treated with platinum and non–platinum-based chemo-
therapy, and as a whole did not show a statistically significant asso-
ciation between the score and OS (low vs high score, log-rank P = 
.88). However, by narrowing the analysis to patients who received 
a platinum and taxane regimen, we found that low score was statis-
tically significantly associated with poor prognosis and high score 
with better prognosis (low vs high score, median OS = 3.6 years 
[95%  CI  =  2.8  to  4.3  years]  vs  4.1  years  [95%   
CI = 3.1 to 5.7 years]; 5-year OS, 18% [95% CI = 7% to 42%] vs 
47% [95% CI = 32% to 63%]; log-rank P = .044).
We hypothesized that there would be decreased reproducibility 
of a score with incorporation of genes without biologic rationale. 
Table 3. Cox proportional hazards model using relevant pretreatment 
predictors*
Variables HR (95% CI) P†
Age, grade, and stage  
  Age, y‡ 1.0051 (0.99 to 1.021) .53
  Grade  
    1 1.00 (referent)
    2 1.36 (0.38 to 8.67) .67
    3 1.45 (0.44 to 8.93) .59
    4 2.47 (0.11 to 26.24) .49
    Unknown 1.54 (0.29 to 11.34) .62
  Stage  
    IIIA 1.00 (referent)
    IIIB 0.93 (0.22 to 6.27) .92
    IIIC 0.87 (0.27 to 5.35) .85
    IV 0.93 (0.27 to 5.88) .93
Age, grade, stage, and score  
  Age, y‡ 1.0039 (0.99 to 1.021) .65
  Grade  
    1 1.00 (referent)
    2 1.41 (0.39 to 9.0063) .64
    3 1.64 (0.50 to 10.087) .47
    4 1.34 (0.061 to 14.40) .82
    Unknown 1.72 (0.33 to 12.72) .53
  Stage  
    IIIA 1.00 (referent)
    IIIB 0.68 (0.16 to 4.66) .65
    IIIC 0.53 (0.16 to 3.26) .42
    IV 0.64 (0.18 to 4.049) .58
  Score§ 0.86 (0.81 to 0.91) <.001
Score alone  
  Score§ 0.86 (0.82 to 0.91) <.001
*  Multivariable analyses using Cox proportional hazards models were performed 
in advanced-stage ovarian cancer patients who received platinum and taxane 
therapy as first-line treatment, to compare models for overall survival with 
and without inclusion of the score, and score alone. Score was assessed as a 
continuous variable, age as a continuous variable, grade 1–4 or unknown as a 
categorical variable, and stage IIIA–C or stage IV as a categorical variable.  
CI = confidence interval; HR = hazard ratio.
†  Two-sided P values were calculated using the Cox proportional hazards models.
‡  HR of death for each year of age at pathological diagnosis greater than 34.
§  HR of death for each unit score greater than 2.
patients. Observational data suggests that ovarian cancer patients 
with  BRCA1  and/or  BRCA2  mutations  may  have  better  overall 
outcome  (48);  thus,  the  association  between  likelihood  of  CR 
based on score and BRCA1 and/or BRCA2 mutation status was 
assessed using the likelihood ratio test. Here, the score was divided 
into  three  categories  (≤7,  8–13,  and  ≥14)  to  better  distinguish 
patients with differing CR rates. All statistical analyses were per-
formed using SAS JMP 9.2 (SAS Institute Inc, Cary, NC). All 
statistical tests were two-sided, and all P values less than .05 were 
considered statistically significant.
Results
Prognostic Value of the Score in Survival of Ovarian Carcinoma 
Patients Treated with Platinum-Based Chemotherapy
From the initial set of 151 DNA repair genes, we selected 23 genes 
from  four  pathways  associated  with  platinum-induced  DNA 
damage (ATM, FA/HR, NER, and TLS pathways), whose expres-
sion levels showed an association (P < .15; this cut point was chosen jnci.oxfordjournals.org    JNCI | Articles 675
Therefore, we repeated our analyses using an alternate 17-gene 
score based on DNA repair pathways unrelated to repair of plat-
inum DNA damage (Supplementary Table 3, available online). 
When this alternate score was applied to the two validation sets, 
we found no statistically significant associations between low vs 
high scores and OS (log-rank P = .29 and .48, in the Berchuck and 
Tothill datasets, respectively) (Supplementary Figure 2, available 
online).
Survival analyses were repeated in the four ovarian cancer 
molecular subtypes (immunoreactive, differentiated, proliferative, 
and mesenchymal) identified by the TCGA based on cluster gene 
content (44), to ascertain whether there was an association between 
subtype and survival outcomes. We found no statistically signifi-
cant difference in survival between the four subtypes in our subset 
of advanced-stage platinum- and taxane-treated patients (log-rank 
P = .33), or in the entire TCGA dataset (log-rank P = .084), for 
which  subtype  information  was  provided.  We  then  applied  the 
score to each of the individual subtypes (Supplementary Figure 3, 
Figure 1. DNA repair pathway–focused score in prognosis of overall 
survival.  For  each  patient’s  tumor,  a  point  was  given  for  each  DNA 
repair gene for which higher than median expression was associated 
with longer survival, and vice versa. The sum of these points consti-
tuted the score. Only genes in pathways related to platinum-induced 
damage  repair  were  included.  Advanced-stage  (stages  III  and  IV) 
ovarian cancer patients from The Cancer Genome Atlas (TCGA) dataset 
who  received  a  platinum  and  taxane  regimen  as  first-line  chemo-
therapy (n = 304) were arbitrarily divided into low (scores 1–10) vs high 
(scores 11–20) scores. A) Kaplan–Meier analysis was used to assess 
median overall survival (OS) and 5-year OS (indicated by black lines) 
from time of pathological diagnosis in low- and high-scoring subgroups. P 
< .001, calculated using a two-sided log-rank test. B) Univariate analysis 
was  performed  using  the  Cox  proportional  hazards  regression 
analyses to assess whether the score was prognostic for OS in the 
TCGA dataset. Solid circles represent hazard ratio (HR) of death and 
open-ended  horizontal  lines  represent  the  95%  confidence  intervals 
(CIs). This was validated in the two published datasets by Berchuck et 
al. (9) and Tothill et al. (11). *P < .05; all P values were calculated using 
Cox proportional hazards analysis.
available online). We observed the greatest statistical significance 
when the score was applied to the mesenchymal subtype (low vs 
high score, median OS, 2.6 years [95% CI = 1.7 to 4.0 years] vs 7.3 
years [95% CI = 3.7 to 9.9 years]; 5-year OS, 18% [95% CI = 8% 
to 40%] vs 79% [95% CI = 50% to 93%]; log-rank P = .0016). 
Distribution of score was also assessed as a continuous and cate-
gorical variable; statistically significant differences in score between 
the subtypes were observed by ANOVA (P < .001 for both).
Predictive Accuracy of the Score Compared With 
Prognostic Clinical Factors
We examined the predictive accuracy of the score compared with 
other clinical factors by performing the Cox proportional hazards 
univariate (Figure 2, A) and multivariable (Figure 2, B) analyses 
using the following factors as categorical variables: score (high vs 
low), treatment response (CR vs none), age (≤59 vs ≥60 years), 
FIGO stage (III vs IV), histological grade (1–2 vs 3), and extent of 
surgical debulking (0–10 vs ≥11 mm residual tumor). In the TCGA 
dataset, only the score and treatment response were statistically 
significantly associated with OS (high vs low scores, HR of death = 
0.40, 95% CI = 0.32 to 0.66, P < .001; CR vs no CR to treatment, 
HR of death = 0.31, 95% CI = 0.20 to 0.43, P < .001). Multivariable 
analysis was repeated in the two validation sets. The score outper-
formed other pretreatment clinical covariates; low score was con-
sistently associated with poor prognosis and high score with better 
prognosis  in  both  validation  datasets  (Berchuck  dataset,  HR  of 
death = 0.30, 95% CI = 0.11 to 0.83, P = .021; and Tothill dataset, 
HR of death = 0.59, 95% CI = 0.34 to 1.01, P = .055) (Figure 2, B), 
whereas all other clinical covariates failed to show a consistent 
association with prognosis. Although we used high vs low score as 
a categorical variable in this analysis, the score also correlated with 
OS when used as a continuous variable (Pearson correlation coef-
ficient [r
2] = 0.47) (Supplementary Figure 4, available online).
To assess the contribution of the score toward prediction of 
response  to  first-line  platinum  and  taxane  therapy,  the  Cox 
proportional hazards statistical models containing relevant pre-
treatment predictors (age, grade, stage, and score) were con-
structed (Table 3), and ROC analyses were performed using the 
following: age, grade, and stage (AGS); age, grade, stage, and score 
(AGS + score); and score alone. For these analyses, survival was 
classified as either higher than or lower than the median OS of 
3.7 years, excluding patients who were alive for durations less than 
the median OS at last follow-up. This demonstrated AUC values 
of 0.60, 0.71, and 0.70, for AGS, AGS + score, and score alone, 
respectively (Figure 3, A). The Berchuck dataset, with median OS 
of 2.4 years, was the only dataset with comparable details available 
for age, histological grade (1–4), and FIGO stage (IIIA, IIIB, IIIC, 
and IV), and was used for validation; the AUC values were 0.52, 
0.65, and 0.65 for AGS, AGS and score, and score alone, respec-
tively (data not shown in the figure).
Next, we analyzed the performance of the score in the four 
ovarian cancer subtypes identified in the TCGA dataset, to deter-
mine whether the score had particularly high predictive accuracy 
in certain subtypes. Thus, ROC analyses were repeated in the four 
ovarian  cancer  subtypes  and  demonstrated  particularly  high 
predictive accuracy of the score in the mesenchymal subtype, with 
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score alone, respectively (Figure 3, B). The remaining subtypes 
had AUC ranges of 0.48–0.69, 0.60–0.69 and 0.58–0.69 for AGS, 
AGS and score, and score alone, respectively (data not shown in 
the figure).
Probability of Achieving CR Based on the Score
Overall,  188  (71%)  of  264  of  patients  with  advanced  epithelial 
ovarian cancer achieved a CR to a platinum and taxane regimen 
(Table 1). To determine whether the score correlated with likeli-
hood of CR, we plotted the percentage of patients achieving CR 
against the score (Pearson correlation coefficient [r
2] = 0.60, P < 
.001) (Figure 4). Patients were classified into lowest, middle, and 
highest tertiles of scores and showed low likelihood (score ≤ 7; 44% 
patients), intermediate likelihood (score 8–13; 73% patients), and 
high likelihood (score ≥ 14; 80%) of CR. Improved survival was 
noted with increasing likelihood of CR (low likelihood, median 
OS = 2.1 years, 95% CI = 1.6 to 2.6 years; intermediate likelihood, 
median OS = 3.8 years, 95% CI = 3.4 to 4.5 years; and high likelihood, 
median OS = 4.6 years, 95% CI = 4.1 to 5.9 years). Interestingly, for 
a score of 14 or higher, the likelihood of CR appeared to plateau at 
approximately 80%, though median OS continued to increase with 
higher score. For example, the subset of patients (n = 43) with score 
14–15 and the subset of patients (n = 32) with score 16 or higher had 
similar likelihoods of CR, but a markedly improved median OS was 
observed in the higher-scoring group (scores 14–15 vs ≥16, 79% vs 
81% likelihood of CR, median OS, 4.6 years [95% CI = 2.9 to 
5.9 years] vs 7.2 years [95% CI = 2.7 to ∞ years]).
Probability of CR and BRCA Mutation Status
In our dataset of advanced platinum- and taxane-treated patients (n 
= 304), 215 had DNA sequencing data available, with 34 (16%) 
germline and seven (3%) somatic BRCA1 and/or BRCA2 muta-
tions. BRCA mutant tumors have defects in homologous recombi-
nation  (49).  Patients  with  germline  BRCA  mutations  have 
tumors with increased sensitivity to platinum therapy and improved 
survival  (50),  likely  secondary  to  compromised  repair  of  DNA 
damage. Tumors with somatic BRCA mutations appear less fre-
quently (51) but are hypothesized to exhibit a “BRCAness” pheno-
type with defective homologous recombination and similarly improved 
outcomes. We therefore examined the breakdown of BRCA1 and 
BRCA2 germline and somatic mutations by scoring category (≤7, 
8–13,  and  ≥14),  which  corresponded  to  low,  intermediate,  and 
high likelihood of CR (44%, 73%, and 80% likelihood of CR), and 
found that the percentage of BRCA germline and somatic muta-
tions increased correspondingly (13% germline and 0% somatic 
mutations for scoring category ≤7, 15% germline and 1% somatic 
mutations for scoring category 8–13, and 19% germline and 5% 
somatic mutations for scoring category ≥14), although this did 
not reach statistical significance (likelihood ratio test P = .18) 
(Supplementary Figure 5, available online).
Prediction of Recurrence-Free Survival and Progression-
Free Survival
Despite achieving a CR, the majority of patients with advanced 
epithelial  ovarian  cancer  eventually  relapse  and  die  of  disease. 
Figure 2. Comparison of the score with prog-
nostic clinical covariates. Univariate and multivar-
iable  Cox  proportional  hazards  regression 
analyses  incorporating  the  score  (high  [scores 
11–20] vs low [scores 0–10]) and known prognos-
tic clinical factors, including response to primary 
therapy (complete response [CR] vs non-CR) by 
Response Evaluation Criteria In Solid Tumors 
(RECIST) criteria (45), age at diagnosis (≤59 
vs  ≥60  years),  International  Federation  of 
Gynecology and Obstetrics (FIGO) (46) stage (III 
vs IV), grade (1–2 vs 3), and extent of surgical 
debulking (0–10 vs ≥11 mm residual tumor); 
each  as  categorical  variables.  Solid  circles 
represent the hazard ratio (HR) of death and   
open-ended horizontal lines represent the 95% 
confidence intervals (CIs). *P < .05; all P values 
were calculated using Cox proportional hazards 
analysis. A) Univariate analysis was performed 
using  Cox  proportional  hazards  regression 
analyses in The Cancer Genome Atlas (TCGA) 
dataset of patients with advanced-stage ((stages 
III and IV) ovarian cancer treated with platinum 
and  taxane  chemotherapy.  B)  Multivariable 
analysis was performed in the TCGA and two 
validation datasets by Berchuck et al. (9) and 
Tothill et al. (11), adjusting for the same cate-
gorical variables.jnci.oxfordjournals.org    JNCI | Articles 677
Although, historically 70% of patients achieve a CR (4), this is 
not the best indicator of overall outcome. This is reflected in our 
dataset; patient subsets with scores of 14–15 vs 16 both had relatively 
high likelihood of CR (Figure 4), but disparate median OS, as stated 
earlier. To explore whether the score could predict additional 
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Figure 3. Receiver operating characteristic (ROC) analysis of the score and 
clinical covariates in predicting overall survival. The area under the curve 
(AUC) was calculated for ROC curves, and sensitivity and specificity was 
calculated to assess score performance. A) Using statistical models con-
structed based on multivariable Cox proportional hazards, ROC curves 
were calculated incorporating clinical variables of age, grade, and stage 
(left); age, grade, stage, and score (middle); and score alone (right). B) ROC 
curves,  including  only  patients  with  tumors  of  mesenchymal  TCGA 
subtype, were also calculated incorporating clinical variables of age, 
grade, and stage (left); age, grade, stage, and score (middle); and score 
alone (right). Grey lines indicate the 45º angle tangent line marked at a 
point that provides best discrimination between true positives and false 
positives, assuming that false positives and false negatives have similar 
costs.
Score
r² = 0.60
Figure 4. Correlation of score with complete response (CR). Advanced-
stage (stages III and IV) ovarian cancer patients from The Cancer Genome 
Atlas (TCGA) dataset who received platinum and taxane as first-line che-
motherapy  (n  =  304  patients)  were  analyzed  based  on  their  individual 
scores. For each patient’s tumor, a point was given for each DNA repair 
gene for which higher than median expression was associated with longer 
survival, and vice versa. The sum of these points constituted our score. The 
percentage of patients achieving CR based on the Response Evaluation 
Criteria In Solid Tumors (RECIST) criteria was calculated for each score 
value and is represented by the black solid circles. The Pearson correlation 
coefficient (r2) was used to assess the relationship between the score and 
likelihood of CR. Patients were classified into lowest (score ≤ 7), middle 
(score 8–13), and highest (score ≥ 14) tertiles (shown in boxes). The straight 
line depicts the least squares linear regression line through the data points.
measures of outcome, we examined RFS in patients who achieved 
a CR to platinum and taxane treatment (Figure 5, A and B). The 
score  was  statistically  significantly  associated  with  RFS  in  this 
cohort (low [0–10] vs high [11–20] scores, median RFS, 1.3 years 
[95% CI = 1.1 to 1.6 years] vs 1.8 years [95% CI = 1.6 to 2.2 years]; 
5-year RFS, 11% [95% CI = 4% to 24%] vs 22% [95% CI = 14% 
to 34%]; log-rank P = .021); there was a statistically significant 
positive correlation between score and duration of RFS (r2 = 0.84, 
P < .001) (Figure 5, B). We analyzed patients with scores of 14–15 vs 
16 or higher and found a trend toward differences in RFS (score 
14–15 vs score 16 or higher, median RFS, 1.8 years [95% CI = 1.3 
to 2.2 years] vs 3.8 years [95% CI = 0.8 to ∞]; 5-year RFS, 13% 
[95% CI = 4 to 32%] vs 43% [95% CI = 20 to 67%]; log-rank P = 
.076). On multivariable analysis (Figure 5, C), only the score was 
statistically significantly associated with RFS (HR of recurrence = 
0.66, 95% CI = 0.45 to 0.98, P = .039) after adjusting for age, stage, 
grade, and extent of surgical debulking. We did not have an appro-
priate dataset in which to validate these findings.
We also examined the ability of the score to predict PFS and 
found a statistically significant difference between scoring groups 
(low [scores 0–10] vs high [scores 11–20] scoring groups, median 
PFS, 1.1 years [95% CI = 0.9 to 1.2 years] vs 1.6 years [95% CI = 
1.3 to 1.8 years]; 5-year PFS, 2.3% [95% CI = 0.4 to 13%] vs 19% 
[95% CI = 13 to 28%]; log-rank P < .001) (Figure 5, D). There was 
a positive correlation between score and duration of PFS (Pearson 
correlation coefficient [r
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We  then  examined  the  distribution  of  responses  in  the  low 
(score 1–10) vs high (score 11–20) scoring group (Supplementary 
Figure  6,  available  online),  to  evaluate  the  association  between 
lower score and likelihood of poor response to treatment as mea-
sured by RECIST criteria. Patients with non-CR to a platinum 
and taxane regimen were categorized as having a PR, SD, or PD 
by RECIST criteria. Out of 265 patients with known response 
data, 21 (8%) patients had PD, with 13 patients (11%) in the   
low-scoring  group  and  eight  patients  (5%)  in  the  high-scoring 
group, suggesting enrichment of patients with PD in the low-scoring 
Figure 5. Ability of the score to predict recurrence-free survival (RFS) 
and progression-free survival (PFS). For each patient’s tumor, a point 
was given for each DNA repair gene for which higher than median 
expression was associated with longer survival, and vice versa. The 
sum of these points constituted our score. Only genes in pathways 
related to platinum-induced damage repair were included. Advanced-
stage  (stages  III  and  IV)  ovarian  cancer  patients  from  The  Cancer 
Genome Atlas (TCGA) dataset who received a platinum and taxane 
regimen as first-line chemotherapy (n = 304 patients) were analyzed to 
assess the relationship between score and RFS and PFS. A) The associ-
ation of score and RFS was assessed in the TCGA ovarian cancer 
patients who achieved a complete response (CR) after receiving the 
first-line platinum and taxane therapy. The Kaplan–Meier method was 
used to compare RFS in patients with low (scores 1–10) vs high (scores 
11–20) scores. *P value was calculated using a two-sided log-rank test. 
B) TCGA ovarian cancer patients who achieved a CR after the first-line 
platinum and taxane therapy were analyzed, by calculating median 
RFS for each score subgroup, represented by the black solid circles. 
The Pearson correlation coefficient (r
2) was calculated to assess the re-
lationship between score and RFS. The straight line depicts the least 
squares linear regression line through the data points. C) Multivariable 
analysis of factors that impact RFS was performed in TCGA ovarian 
cancer patients who achieved a CR following platinum and taxane che-
motherapy.  Cox  proportional  hazards  regression  was  performed  for 
score (high, 11–20, vs low, 1–10), treatment response (CR vs no CR), age 
(≤59  vs  ≥60  years),  International  Federation  of  Gynecology  and 
Obstetrics (FIGO) stage (III vs IV), grade (1–2 vs 3), and extent of surgical 
debulking (0–10 vs ≥11 mm). Solid circles represent the hazard ratio 
(HR) of death and open-ended horizontal lines represent the 95% confi-
dence intervals (CIs). *P values were calculated using a two-sided 
log-rank test. D) The association of score and PFS was assessed in the 
TCGA ovarian cancer patients with available data. The Kaplan–Meier 
method was used to compare PFS in patients with low (scores 1–10) vs 
high (scores 11–20) scores. *P value was calculated using a two-sided 
log-rank test. E) TCGA ovarian cancer patients with PFS data were ana-
lyzed, by calculating median PFS for each score subgroup, represented 
by the black solid circles. The Pearson correlation coefficient (r
2) was 
calculated  to  assess  the  relationship  between  score  and  PFS.  The 
straight line depicts the least squares linear regression line through the 
data points.jnci.oxfordjournals.org    JNCI | Articles 679
group. This is consistent with the poor prognosis of patients with 
progressive or platinum-refractory disease.
Discussion
In this study, we demonstrate that a hypothesis-driven approach 
can be used to produce a reproducible gene expression–based 
score. By selecting genes in pathways known to be involved in 
repair of platinum-induced DNA damage, we produced a score 
that is predictive of OS, PFS, and RFS in ovarian cancer patients 
following platinum-based chemotherapy. Moreover, we were able 
to validate our results in two additional datasets of advanced-stage 
ovarian cancer patients treated with platinum-based chemotherapy 
and demonstrate that the score is prognostic for survival only when 
it is composed of genes from relevant DNA repair pathways, further 
strengthening the use of biologic rationale in molecular signature 
construction.
We were also able to demonstrate that the score outperforms 
other  known  clinical  factors  in  predicting  OS,  not  only  in  the 
TCGA dataset but also in two additional validation sets. Developing 
the ability to predict OS and outcomes to chemotherapy using 
prognostic  markers  such  as  the  score  is  critical,  particularly  in 
ovarian cancer, because there are presently no other good clinical 
measures to predict response to standard platinum-based chemo-
therapy. As a result, although 30% of patients receive no benefit 
from  standard  platinum-based  chemotherapy,  many  patients 
undergo multiple cycles of futile, potentially toxic treatment.
With further validation, the score can become an important tool 
that can be used in such advanced-stage ovarian cancer patients 
before initiation of first-line therapy to help direct them toward 
treatments  with  the  greatest  benefit/risk  ratio.  Patients  in  the 
lowest scoring category of 7 or less, with a median OS of 2.1 years, 
stand to benefit the most from alternate therapies, such as enroll-
ment in phase I clinical trials or treatments that target alternate 
DNA repair pathways, such as radiation. A Gynecologic Oncology 
Group (GOG) phase I study, GOG-9915, was recently published 
using low-dose abdominal radiation along with docetaxel in recur-
rent epithelial ovarian cancer patients, with acceptable toxicity and 
promising  results  in  a  subset  of  patients;  30%  of  patients  with 
measurable disease achieved greater than 6 months PFS (4). In 
addition, topotecan, a topoisomerase poison that has an alternate 
mechanism of action than platinum, has been tested in clinical 
trials with demonstrated efficacy in platinum-resistant cohorts (5).
Conversely, patients in the highest scoring category of 14 and 
above derive the greatest most durable benefit from platinum and 
taxane chemotherapy. The enrichment of BRCA1/2 germline and 
somatic  mutations  in  this  group  suggests  this  subset  exhibits  a 
BRCA-like phenotype (“BRCAness”). High CR rates to platinum, 
improved OS, and defective HR are characteristics of “BRCAness” 
that predict for excellent response to poly-ADP ribose polymerase 
(PARP) inhibition (51,52). This is consistent with recently pub-
lished results showing even among BRCA-mutant epithelial ovarian 
cancer tumors, platinum-sensitive tumors exhibit the highest response 
rates  (61%)  compared  with  platinum-resistant  and  platinum-
refractory BRCA-mutant tumors (41% and 15%, respectively) 
(53). Therefore, we hypothesize that patients in our highest scoring 
category are the subset of patients that would benefit most from 
PARP inhibitor therapy, regardless of BRCA status. This would 
greatly expand the number of patients who stand to benefit from 
this promising treatment.
Gene expression profiling has immense potential to aid in 
predicting patient outcomes. The recent release of TCGA gene 
expression data in epithelial ovarian cancer is unprecedented in 
size  and  comprehensiveness  (44).  By  mining  this  resource,  and 
applying biologic rationale, we have created a durable score that 
provides  predictive  information  regarding  a  tumor’s  intrinsic 
sensitivity or resistance to first-line platinum and taxane chemo-
therapy. It outperforms traditional predictors of clinical outcome 
(age, grade, and stage) for both OS and RFS, with high predictive 
accuracy. A statistical model including age, grade, and stage was 
notably improved by addition of the score and performed trivially 
better than the score alone based on AUC results. The fact that the 
score  performs  particularly  well  in  the  mesenchymal  tumor 
subtype suggests that this group is especially dependent on DNA 
repair capability and merits further investigation.
The study has a few limitations. Although we recapitulated our 
findings in two published datasets to the extent possible based on 
data availability, the score has not yet been tested prospectively in 
a clinical trial. We believe the score is ready for such testing, which 
must be performed before more widespread adoption in ovarian 
cancer patients as a prognostic tool. Also, gene expression profiling 
captures only a subset of cancer genetic and epigenetic changes. 
Many genes are not regulated at the transcriptional level, and thus 
their expression levels are noninformative. Other mechanisms of 
regulation include microRNAs (54), protein phosphorylation (55), 
and  ubiquitination  (56).  To  address  this  problem,  we  selected 
only those genes whose expression levels were associated with 
survival. High vs low levels of relative gene expression do not 
necessarily reflect function; for instance, a high level of expres-
sion may reflect an attempt to compensate for a defective path-
way.  More  direct  assays  of  DNA  repair  pathway  activity  may 
address this but would be more complex to implement in routine 
clinical practice.
In conclusion, by using a hypothesis-driven approach, we have 
generated a DNA repair pathway–focused score that could be 
validated in two additional datasets. With additional prospective 
validation in clinical trials, we hope that the score can become a 
powerful tool that is useful in stratifying advanced-stage ovarian 
cancer patients toward optimal treatments incorporating new 
treatment regimens vs current standard of care.
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